Vycor Medical Inc. Files Q3 2024 10-Q
Ticker: VYCO · Form: 10-Q · Filed: Nov 13, 2024 · CIK: 1424768
| Field | Detail |
|---|---|
| Company | Vycor Medical Inc (VYCO) |
| Form Type | 10-Q |
| Filed Date | Nov 13, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, reporting
TL;DR
Vycor Medical Q3 10-Q filed. Check financials.
AI Summary
Vycor Medical Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter. Specific financial figures and operational highlights are presented within the report.
Why It Matters
This filing provides investors and stakeholders with the latest financial health and strategic direction of Vycor Medical Inc. as of Q3 2024.
Risk Assessment
Risk Level: low — This is a standard quarterly filing with no immediate red flags or significant new risks highlighted.
Key Players & Entities
- VYCOR MEDICAL INC (company) — Filer
- 20240930 (date) — Period of Report
- 20241113 (date) — Filing Date
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240930, indicating the filing covers the period ending September 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20241113.
What is Vycor Medical Inc.'s Standard Industrial Classification?
Vycor Medical Inc.'s SIC code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
What are the business and mailing addresses for Vycor Medical Inc.?
The business and mailing address for Vycor Medical Inc. is 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487.
What is the company's fiscal year end?
Vycor Medical Inc.'s fiscal year ends on 1231.
Filing Stats: 4,750 words · 19 min read · ~16 pages · Grade level 17.5 · Accepted 2024-11-13 12:02:48
Filing Documents
- form10-q.htm (10-Q) — 1550KB
- ex31-1.htm (EX-31.1) — 11KB
- ex31-2.htm (EX-31.2) — 11KB
- ex32-1.htm (EX-32.1) — 4KB
- ex32-2.htm (EX-32.2) — 4KB
- 0001493152-24-045025.txt ( ) — 6115KB
- vyco-20240930.xsd (EX-101.SCH) — 33KB
- vyco-20240930_cal.xml (EX-101.CAL) — 59KB
- vyco-20240930_def.xml (EX-101.DEF) — 189KB
- vyco-20240930_lab.xml (EX-101.LAB) — 280KB
- vyco-20240930_pre.xml (EX-101.PRE) — 247KB
- form10-q_htm.xml (XML) — 1038KB
SIGNATURES
SIGNATURES 23 2 PART 1 ITEM 1. FINANCIAL STATEMENTS VYCOR MEDICAL, INC. Consolidated Balance Sheets (Unaudited) September 30, December 31, 2024 2023 ASSETS Current Assets Cash $ 157,633 $ 57,291 Trade accounts receivable 238,700 215,231 Inventory 187,627 234,145 Prepaid expenses and other current assets 158,500 76,684 Current assets of discontinued operations 970 739 Total Current Assets 743,430 584,090 Fixed assets, net 209,732 252,404 Intangible and Other assets: Security deposits 6,000 6,000 Operating lease - right of use assets 115,442 149,804 Total Intangible and Other assets 121,442 155,804 TOTAL ASSETS $ 1,074,604 $ 992,298 LIABILITIES AND STOCKHOLDERS' DEFICIENCY Current Liabilities Accounts payable $ 150,980 $ 117,801 Accrued interest: Other 508,931 472,897 Accrued interest: Related Party 232,965 195,522 Accrued interest 232,965 195,522 Accrued liabilities - Other 187,995 151,816 Dividends payable - Related Party 2,594,960 2,270,590 Notes payable: Related Party 493,373 493,373 Notes payable: Other 337,179 328,267 Notes payable 337,179 328,267 Current operating lease liabilities 47,178 45,321 Current liabilities of discontinued operations ( 672 ) ( 1,100 ) Total Current Liabilities 4,552,889 4,074,487 Operating lease liability - long term 64,745 100,379 Loan payable - SBA EIDL 140,316 142,908 Total Liabilities 4,757,950 4,317,774 STOCKHOLDERS' DEFICIENCY Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized Preferred C Stock, 1 and 1 share issued and outstanding as at September 30, 2024 and December 31, 2023 respectively - - Preferred D Stock, 270,306 and 270,306 shares issued and outstanding as at September 30, 2024 and December 31, 2023 respectively 27 27 Preferred Stock, Value 27 27 Common Stock, $ 0.0001 par value, 55,000,000 shares authorized at September 30, 2024 and December 31, 2023, 33